Drug-induced liver injury or DILI is the leading reason
for a drug that is approved by the Drug Administration to subsequently be
withdrawn from the market.
DILI can result from both prescribed and over-the-counter
(OTC) agents, including some herbal and dietary supplements. It is both
difficult to predict and challenging to recognize.
Hy’s law: Jaundice (bilirubin >2 times upper limit of
normal [ULN]) in combination with elevated serum aminotransferase levels (>3
times ULN) has the worst prognosis. These findings in a patient with a
hepatocellular pattern of injury are associated with high mortality rates
(10-50%) without transplantation. This pattern was first identified by Hyman
Zimmerman and is now called Hy’s law.
Categorizing DILI on the basis of the three injury
patterns—hepatocellular, cholestatic, and mixed hepatocellular-cholestatic may
not characterize the injury completely. A clinical phenotype is also
used; 12 DILI phenotypes have been described.
1. Acute hepatic necrosis
2. Acute hepatitis
3. Cholestatic hepatitis
4. Mixed hepatocellular-cholestatic hepatitis
5. Enzyme elevations without jaundice
·
Hepatocellular
·
Cholestatic
·
Mixed
6. Bland cholestasis
7. Hepatic steatosis and lactic acidosis
8. Nonalcoholic fatty liver
9. Chronic hepatitis
10. Sinusoidal obstruction syndrome (veno-occlusive
disease)
11. Nodular regenerative hyperplasia
12. Hepatic adenoma and hepatocellular carcinoma
The 12 phenotypes can have distinctive immunological
features:
·
Immunoallergic
·
Autoimmune
The 12 phenotypes also have adverse outcomes:
·
Acute liver failure
·
Vanishing bile duct syndrome
·
Cirrhosis
Paracetamol is the leading cause of DILI. However,
only about half of cases occur due to intentional overdose; the remaining half
are due to chronic use or unintentional overdoses. Long-term use of
supratherapeutic amounts is more toxic and recognized later than a single
ingestion; therefore, these patients have higher rates of severe
hepatotoxicity, liver-related complications and death, as compared to those who
have attempted suicide with paracetamol.
Alcohol- and paracetamol-linked DILI: Ingesting
alcohol and acetaminophen together does not increase the risk for
hepatotoxicity due to the paracetamol. Alcohol, as a substrate of CYP2E1, may
lower the risk for liver injury by competing with paracetamol for the enzymes
thus decreasing the amount of the toxic metabolite produced. The role of
chronic alcohol ingestion is controversial. A lower daily dose of paracetamol
is recommended for these patients.
Patients with advanced liver disease should also limit
their paracetamol intake.
Cirrhosis, regardless of the etiology, reduces the metabolism of acetaminophen.
Therefore, patients with either an alcohol use disorder or underlying liver
disease should be advised to limit their daily amount of acetaminophen to less
than 2 g/day.
Risk for DILI from statins: Mild to moderate
transient asymptomatic elevations in serum aminotransferase levels are common
with statins. This phenomenon occurs early after the initiation of therapy but eventually
normalizes, despite ongoing therapy. So, this is a lab abnormality and not a
true liver injury; liver biopsy shows no histopathologic change.
According to the Drug-Induced Liver Injury Network
(DILIN), only 3.4% of reported drug-induced liver injuries were linked to
statins. Growing evidence also shows that statins may actually reduce the risk
for liver cancer and improve outcomes in those diagnosed with hepatocellular
carcinoma.
Clinicians should not be afraid to use this class of
agents to reduce the risk for cardiovascular disease.
Herbal does not mean risk-free. The DILIN
found that 15%-20% of DILI cases could be attributed to herbal and dietary
supplements. Most liver injury that is induced by herbal and dietary
supplements is attributed to bodybuilding agents (anabolic steroids), green tea
extract, and multi-ingredient nutritional supplements, many of which also list
green tea as a component. Others implicated include those for weight loss,
depression, sexual performance, gastrointestinal upset, immune support and
joint support, as well as Chinese herbs.
(Source: Medscape; LiverTox, National Institute of
Health)
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of
Medical Associations in Asia and Oceania
(CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of
India
Past National President
IMA
No comments:
Post a Comment